Shigeto Kanada
Oasis Hospital(AE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Smoking Behavior and Cessation, Blood Pressure and Hypertension Studies, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → Azelnidipine and Amlodipine: a Comparison of Their Pharmacokinetics and Effects on Ambulatory Blood Pressure.(2003)112 cited
- → Sodium‐glucose co‐transporter‐2 inhibitor use and dietary carbohydrate intake in J apanese individuals with type 2 diabetes: A randomized, open‐label, 3‐arm parallel comparative, exploratory study(2016)67 cited
- → Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in J apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study(2015)49 cited
- → Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients(2011)45 cited
- → Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus(2013)42 cited
- → Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 6: 6-day randomized clinical trial of a menthol cigarette in Japan(2012)23 cited
- → Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 5: 8-Day randomized clinical trial in Japan(2012)22 cited
- → 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol(2010)22 cited
- → Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive ― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study ―(2017)16 cited
- → Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes(2025)4 cited